Compare Davita Inc (DVA) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs KeyCorp — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while KeyCorp trades at $20.1 (market cap $21.16B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays a 4.14% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and KeyCorp for 66 Days on average.
| DVA | KEY | |
|---|---|---|
Market Cap | $11.28B | $21.16B |
Volume | 650,294 | 16,207,672 |
Sector | Health | Financials |
52-Week High | $240.96 | $23.99 |
52-Week Low | $103.87 | $16.78 |
Typical Hold Time | 113 Days | 66 Days |
Enterprise Value | $24.00B | $34.34B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
KeyCorp (KEY) trades at $20.1, down 0.2% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The stock shows attractive valuation with a P/E of 11.6 and a P/B of 1.22, supported by a strong net income margin of 26.72%. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments aimed at strengthening operations.
The outlook is positive with a consensus price target of $25.00, implying significant upside, driven by loan growth and net interest margin expansion. Risks include competitive pressure from peers raising dividends and macroeconomic sensitivity to interest rate changes. Earnings momentum and institutional buying provide a solid foundation for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
